Release Date: November 26, 2025
Expiration Date: November 26, 2026
Activity Overview
In the rapidly expanding oncology treatment landscape, multidisciplinary care is essential for managing any treatment-related adverse events. This program will provide eye care clinicians with the knowledge and competence to manage ocular toxicities associated with antibody-drug conjugates, monoclonal antibodies, and selective estrogen receptor degraders to optimize patient outcomes. It is an archived webcast of a live program presented on October 18, 2025.
Target Audience
This educational activity is directed toward ophthalmologists, optometrists, medical oncologists, advanced practice providers, nurses, and other health care providers involved in the management of patients with cancer who are at risk of ocular adverse events due to their treatment regimen.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the mechanisms of emerging targeted cancer therapies that can lead to ocular toxicities.
- Apply evidence-based strategies for the early identification, monitoring, and management of ocular adverse events in patients with cancer treated with targeted therapies.
- Apply multidisciplinary strategies to optimize coordinated care between oncology and eye care specialists in managing ocular toxicities.
- Integrate shared decision-making to promote patient awareness, engagement, and timely reporting of ocular symptoms.
Neel Pasricha, MD
Assistant Professor of Ophthalmology
Cornea, External Disease, and Refractive Surgery
Francis I. Proctor Foundation
University of California, San Francisco
San Francisco, CA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Amgen, AstraZeneca, Glaukos, GlaxoSmithKline, Hexagon Bio, Iksuda Therapeutics, Sanofi, Vanda Pharmaceuticals; Ownership interests in privately held companies: Diatiro, Globe Biomedical
Meghan Berkenstock, MD
Associate Professor of Ophthalmology
Wilmer Eye Institute
Johns Hopkins School of Medicine
Baltimore, MD
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, GSK, Sanofi
Asim Farooq, MD
Professor
Vice Chair for Academic Affairs
Director of Medical Student Education
Department of Ophthalmology and Visual Science
University of Chicago
Chicago, IL
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Ambrx, Amgen, AstraZeneca, Boehringer Ingelheim, Corbus Pharmaceuticals, Eisai, GlaxoSmithKline, Mythic Therapeutics, Sanofi, Seagen, Skye Bioscience
Kapil Mishra, MD
Assistant Clinical Professor of Ophthalmology
Gavin Herbert Eye Institute
University of California, Irvine
Irvine, CA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Zeiss
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here